Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection

Shelly S. Lo, Patricia B. Mumby, John Norton, Karen Rychlik, Jeffrey Smerage, Joseph Kash, Helen K. Chew, Ellen R. Gaynor, Daniel F. Hayes, Andrew Epstein, Kathy S. Albain

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

Purpose: The 21-gene Recurrence Score (RS) assay has been validated to quantify the risk of distant recurrence in tamoxifen-treated patients with lymph node-negative, estrogen receptor-positive breast cancer and predict magnitude of chemotherapy benefit. This multicenter study was designed to prospectively examine whether RS affects physician and patient adjuvant treatment selection and satisfaction. Patients and Methods: Before and after obtaining the 21-gene RS assay, medical oncologists stated their adjuvant treatment recommendation and confidence in it. Patients also indicated their treatment choice pre- and post-RS assay. Patients completed measures for decisional conflict, anxiety, and quality of life. Results: Seventeen medical oncologists at one community and three academic practices consecutively enrolled 89 assessable patients. The medical oncologist treatment recommendation changed for 28 patients (31.5%). Twenty-four patients (27%) changed their treatment decision. The largest change after the RS results was conversion from the medical oncologist's pretest recommendation for chemotherapy plus hormonal therapy (CHT) to post-test recommendation for hormone therapy (HT) in 20 cases (22.5%). Nine patients (10.1%) changed their treatment decision from CHT to HT. RS results increased medical oncologist confidence in their treatment recommendation in 68 cases (76%). Patient anxiety and decisional conflict were significantly lower after RS results. Conclusion: The results of this study indicate that the RS assay impacts medical oncologist adjuvant treatment recommendations, patient treatment choice, and patient anxiety.

Original languageEnglish (US)
Pages (from-to)1671-1676
Number of pages6
JournalJournal of Clinical Oncology
Volume28
Issue number10
DOIs
StatePublished - Apr 1 2010

Fingerprint

Multicenter Studies
Prospective Studies
Breast Neoplasms
Recurrence
Genes
Therapeutics
Anxiety
Drug Therapy
Oncologists
Hormones
Tamoxifen
Estrogen Receptors
Lymph Nodes
Quality of Life
Physicians

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. / Lo, Shelly S.; Mumby, Patricia B.; Norton, John; Rychlik, Karen; Smerage, Jeffrey; Kash, Joseph; Chew, Helen K.; Gaynor, Ellen R.; Hayes, Daniel F.; Epstein, Andrew; Albain, Kathy S.

In: Journal of Clinical Oncology, Vol. 28, No. 10, 01.04.2010, p. 1671-1676.

Research output: Contribution to journalArticle

Lo, Shelly S. ; Mumby, Patricia B. ; Norton, John ; Rychlik, Karen ; Smerage, Jeffrey ; Kash, Joseph ; Chew, Helen K. ; Gaynor, Ellen R. ; Hayes, Daniel F. ; Epstein, Andrew ; Albain, Kathy S. / Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 10. pp. 1671-1676.
@article{2478b143f0ef4c1283511663b35bd530,
title = "Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection",
abstract = "Purpose: The 21-gene Recurrence Score (RS) assay has been validated to quantify the risk of distant recurrence in tamoxifen-treated patients with lymph node-negative, estrogen receptor-positive breast cancer and predict magnitude of chemotherapy benefit. This multicenter study was designed to prospectively examine whether RS affects physician and patient adjuvant treatment selection and satisfaction. Patients and Methods: Before and after obtaining the 21-gene RS assay, medical oncologists stated their adjuvant treatment recommendation and confidence in it. Patients also indicated their treatment choice pre- and post-RS assay. Patients completed measures for decisional conflict, anxiety, and quality of life. Results: Seventeen medical oncologists at one community and three academic practices consecutively enrolled 89 assessable patients. The medical oncologist treatment recommendation changed for 28 patients (31.5{\%}). Twenty-four patients (27{\%}) changed their treatment decision. The largest change after the RS results was conversion from the medical oncologist's pretest recommendation for chemotherapy plus hormonal therapy (CHT) to post-test recommendation for hormone therapy (HT) in 20 cases (22.5{\%}). Nine patients (10.1{\%}) changed their treatment decision from CHT to HT. RS results increased medical oncologist confidence in their treatment recommendation in 68 cases (76{\%}). Patient anxiety and decisional conflict were significantly lower after RS results. Conclusion: The results of this study indicate that the RS assay impacts medical oncologist adjuvant treatment recommendations, patient treatment choice, and patient anxiety.",
author = "Lo, {Shelly S.} and Mumby, {Patricia B.} and John Norton and Karen Rychlik and Jeffrey Smerage and Joseph Kash and Chew, {Helen K.} and Gaynor, {Ellen R.} and Hayes, {Daniel F.} and Andrew Epstein and Albain, {Kathy S.}",
year = "2010",
month = "4",
day = "1",
doi = "10.1200/JCO.2008.20.2119",
language = "English (US)",
volume = "28",
pages = "1671--1676",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection

AU - Lo, Shelly S.

AU - Mumby, Patricia B.

AU - Norton, John

AU - Rychlik, Karen

AU - Smerage, Jeffrey

AU - Kash, Joseph

AU - Chew, Helen K.

AU - Gaynor, Ellen R.

AU - Hayes, Daniel F.

AU - Epstein, Andrew

AU - Albain, Kathy S.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Purpose: The 21-gene Recurrence Score (RS) assay has been validated to quantify the risk of distant recurrence in tamoxifen-treated patients with lymph node-negative, estrogen receptor-positive breast cancer and predict magnitude of chemotherapy benefit. This multicenter study was designed to prospectively examine whether RS affects physician and patient adjuvant treatment selection and satisfaction. Patients and Methods: Before and after obtaining the 21-gene RS assay, medical oncologists stated their adjuvant treatment recommendation and confidence in it. Patients also indicated their treatment choice pre- and post-RS assay. Patients completed measures for decisional conflict, anxiety, and quality of life. Results: Seventeen medical oncologists at one community and three academic practices consecutively enrolled 89 assessable patients. The medical oncologist treatment recommendation changed for 28 patients (31.5%). Twenty-four patients (27%) changed their treatment decision. The largest change after the RS results was conversion from the medical oncologist's pretest recommendation for chemotherapy plus hormonal therapy (CHT) to post-test recommendation for hormone therapy (HT) in 20 cases (22.5%). Nine patients (10.1%) changed their treatment decision from CHT to HT. RS results increased medical oncologist confidence in their treatment recommendation in 68 cases (76%). Patient anxiety and decisional conflict were significantly lower after RS results. Conclusion: The results of this study indicate that the RS assay impacts medical oncologist adjuvant treatment recommendations, patient treatment choice, and patient anxiety.

AB - Purpose: The 21-gene Recurrence Score (RS) assay has been validated to quantify the risk of distant recurrence in tamoxifen-treated patients with lymph node-negative, estrogen receptor-positive breast cancer and predict magnitude of chemotherapy benefit. This multicenter study was designed to prospectively examine whether RS affects physician and patient adjuvant treatment selection and satisfaction. Patients and Methods: Before and after obtaining the 21-gene RS assay, medical oncologists stated their adjuvant treatment recommendation and confidence in it. Patients also indicated their treatment choice pre- and post-RS assay. Patients completed measures for decisional conflict, anxiety, and quality of life. Results: Seventeen medical oncologists at one community and three academic practices consecutively enrolled 89 assessable patients. The medical oncologist treatment recommendation changed for 28 patients (31.5%). Twenty-four patients (27%) changed their treatment decision. The largest change after the RS results was conversion from the medical oncologist's pretest recommendation for chemotherapy plus hormonal therapy (CHT) to post-test recommendation for hormone therapy (HT) in 20 cases (22.5%). Nine patients (10.1%) changed their treatment decision from CHT to HT. RS results increased medical oncologist confidence in their treatment recommendation in 68 cases (76%). Patient anxiety and decisional conflict were significantly lower after RS results. Conclusion: The results of this study indicate that the RS assay impacts medical oncologist adjuvant treatment recommendations, patient treatment choice, and patient anxiety.

UR - http://www.scopus.com/inward/record.url?scp=77950494285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950494285&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.20.2119

DO - 10.1200/JCO.2008.20.2119

M3 - Article

C2 - 20065191

AN - SCOPUS:77950494285

VL - 28

SP - 1671

EP - 1676

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -